Oseltamivir dosing in premature infants

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 847-850

  McPherson, Christopher ^a   Warner, Barbara ^b   Hunstad, David A ^b   Elward, Alexis ^b   Acosta, Edward P ^c  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; INFANT; INFLUENZA; INFLUENZA VIRUS A; NOSE SMEAR; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ABSORPTION; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; KIDNEY; MODELS, BIOLOGICAL; OSELTAMIVIR; PROSPECTIVE STUDIES;

EID: 84865764387     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis471     Document Type: Article

References (15)

1. Kimberlin D, Acosta E, Sanchez P, et al.; for NIAID Collaborative Antiviral Study Group (CASG). Oseltamivir (OST) and OST carboxylate (CBX) pharmacokinetics (PK) in infants: interim results from a multicenter trial. In: Program and abstracts of the 47th Annual Meeting of The Infectious Diseases Society of America. Philadelphia, Pennsylvania. 2009 Abstract 1041.
2. Tamiflu package insert. http://www.rocheusa.com/products/tamiflu/pi. pdf. Accessed 27 November 2011.
3. Abdel-Rahman SM, Newland JG, Kearns GL. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs 2011; 13:19-31.
4. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353:2559-67.
5. FDA. Issuance letter for Tamiflu. 2003. http://www.fda.gov/down loads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedi calProducts/UCM169493.pdf. Accessed 27 November 2011.
6. Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol 2011; 31:487-93.
7. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010; 29:495-8.
8. Okamoto S, Kamiya I, Kishida K, Shimakawa T, Fukui T, Morimoto T. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005; 24:575-6.
9. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
10. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202:563-6.
11. Wiltshire H, Wiltshire B, Citron A, et al. Development of a highperformance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 2000; 745:373-88.
12. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 2009.
13. Oo C, Hill G, Dorr A, et al. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol 2003; 59:411-5.
14. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
15. Shi D, Yang D, Prinssen EP, Davies BE, Yan B. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J Infect Dis 2011; 203:937-42.